Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
On examination, the temperature was 36.1°C, the blood...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Given the wide availability and low cost of ivermectin and...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
30 mar 2024 · The effect of ivermectin (IVM) in treating coronavirus disease 2019 (COVID-19) is still controversial, yet the drug has been widely used in the world. The aim of this review was to systematically evaluate the clinical outcomes of IVM in patients with COVID-19.
Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Manjhi PK, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.
14 gru 2022 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients...
Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.
This study was designed with the primary objective of estimating the association of ivermectin treatment with mortality in patients admitted with COVID-19. A secondary objective was the estimation of the extent of reduction, if any, in duration of hospital stay in survivors who received ivermectin.
We found 14 studies with 1678 participants that investigated ivermectin compared to no treatment, placebo, or usual care. For treatment, there were nine studies of people with moderate COVID-19 in hospital and four of outpatients with mild COVID-19.